William Genthe

William Genthe

Auto-generated profile, based on publicly available information

William Genthe

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
STSantiago Thibaud
Santiago Thibaud
RSRyan L. Subaran
Ryan L. Subaran
SNScott Newman
Scott Newman
ALAlessandro Laganà
Alessandro Laganà
DMDavid T. Melnekoff
David T. Melnekoff
KOKenan Onel
Kenan Onel
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk and outcomes is not well characterized. To address this, we analyzed germline exomes in two independent cohorts of 895 and 786 patients with multiple myeloma. PGVs were identified in 8.6% of the Discovery cohort and 11.5% of the Replication cohort, with a notable presence of high- or moderate-penetrance PGVs (associated with autosomal dominant cancer predisposition) in DNA repair genes (3.6% and 4.1%, respectively). PGVs in BRCA1 (OR = 3.9, FDR < 0.01) and BRCA2 (OR = 7.0, FDR < 0.001) were significantly enriched in patients with multiple myeloma when compared with 134,187 healthy controls. Five of the eight BRCA2 PGV carriers exhibited tumor-specific copy number loss in BRCA2, suggesting somatic loss of heterozygosity. PGVs associated with autosomal dominant cancer predisposition were associated with younger age at diagnosis, personal or familial cancer history, and longer progression-free survival after upfront high-dose melphalan and autologous stem-cell transplantation (P < 0.01). Significance: Our findings suggest up to 10% of patients with multiple myeloma may have an unsuspected cancer predisposition syndrome. Given familial implications and favorable outcomes with high-dose melphalan and autologous stem-cell transplantation in high-penetrance PGV carriers, genetic testing should be considered for young or newly diagnosed patients with a personal or family cancer history. See related commentary by Walker, p. 375

31 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
GSGiangela Stokes
Giangela Stokes
ZLZhuowei Li
Zhuowei Li
NTNicole Talaba
Nicole Talaba
WGWilliam Genthe
William Genthe
MBMaria B. Brix
Maria B. Brix
DMDavid McCulley
David McCulley
A major barrier to the impact of genomic diagnosis in patients with congenital malformations is the lack of understanding regarding how sequence variants contribute to disease pathogenesis and whether this information could be used to generate patient-specific therapies. Congenital diaphragmatic hernia (CDH) is among the most common and severe of all structural malformations; however, its underlying mechanisms are unclear. We identified loss-of-function sequence variants in the epigenomic regulator geneSIN3Ain two patients with complex CDH. Tissue-specific deletion ofSin3ain mice resulted in defects in diaphragm development, lung hypoplasia, and pulmonary hypertension, the cardinal features of CDH and major causes of CDH-associated mortality. Loss of SIN3A in the lung mesenchyme resulted in reduced cellular differentiation, impaired cell proliferation, and increased DNA damage. Treatment of embryonicSin3amutant mice with anacardic acid, an inhibitor of histone acetyltransferase, reduced DNA damage, increased cell proliferation and differentiation, improved lung and pulmonary vascular development, and reduced pulmonary hypertension. These findings demonstrate that restoring the balance of histone acetylation can improve lung development in theSin3amouse model of CDH.

17 June 2026
Verified
Other
Open access
PDF file
STSantiago Thibaud
Santiago Thibaud
RSRyan L. Subaran
Ryan L. Subaran
SNScott Newman
Scott Newman
ALAlessandro Laganà
Alessandro Laganà
DMDavid T. Melnekoff
David T. Melnekoff
KOKenan Onel
Kenan Onel
SUPPLEMENTARY FIGURE 2: Overall Survival (OS) in PGV-A carriers vs non-carriers

17 June 2026
Verified
Other
Open access
STSantiago Thibaud
Santiago Thibaud
RSRyan L. Subaran
Ryan L. Subaran
SNScott Newman
Scott Newman
ALAlessandro Laganà
Alessandro Laganà
DMDavid T. Melnekoff
David T. Melnekoff
KOKenan Onel
Kenan Onel
SUPPLEMENTARY TABLE 8: Assessment of Loss of Heterozygosity (LOH) in Carriers of PGVs in BRCA1 and BRCA2

17 June 2026
Verified
Other
Open access
STSantiago Thibaud
Santiago Thibaud
RSRyan L. Subaran
Ryan L. Subaran
SNScott Newman
Scott Newman
ALAlessandro Laganà
Alessandro Laganà
DMDavid T. Melnekoff
David T. Melnekoff
KOKenan Onel
Kenan Onel
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma

1 November 2024
Verified
Other
Open access
STSantiago Thibaud
Santiago Thibaud
RSRyan L. Subaran
Ryan L. Subaran
SNScott Newman
Scott Newman
ALAlessandro Laganà
Alessandro Laganà
DMDavid T. Melnekoff
David T. Melnekoff
KOKenan Onel
Kenan Onel
SUPPLEMENTARY TABLE 2: PGV Classification and Allele Count by Cohort